We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





New Line of Immunoassay Stabilizers Launched at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: Immunoassay stabilizers give assay developers the best possible tool to lower non-specific binding and maximize the signal-to-noise ratios of immunoassays (Photo courtesy of Surmodics).
Image: Immunoassay stabilizers give assay developers the best possible tool to lower non-specific binding and maximize the signal-to-noise ratios of immunoassays (Photo courtesy of Surmodics).
The launch and immediate availability of a new line of advanced immunoassay stabilizers were announced prior to the commencement of the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

The Surmodics (Eden Prairie, MN, USA) StabilBlock Immunoassay Stabilizer, which will be on display in Booth 4047 of the expo, is advertised as the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.

Surmodics offers a family of immunoassay stabilizers, which preserve the conformation and activity of dried proteins on a wide range of surfaces, keeping antibodies and antigens at peak performance for long durations. At the same time, the blocking mechanisms in these reagents reduce non-specific binding of interfering proteins to maximize assay sensitivity. With StabilCoat, StabilGuard, and the new StabilBlock immunoassay stabilizers, the company now offers three options to assay developers with a combination of blocking efficacy and long-term dried stability that is unmatched in the industry.

“As part of our commitment to being the premier provider of IVD assay components to improve performance and manufacturability of immunoassays, we continue to advance our offerings to meet the needs of our customers,” said Joe Stich, vice- president and general manager of Surmodics IVD. “We recognize that each assay has its own blocking requirements and our expanded portfolio of Immunoassay Stabilizers will enable assay developers to achieve the best results for each application.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Surmodics



Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Modular Clinical Chemistry Analyzer
CMD 800X1/CMD 800iX1
New
ELISA & CLIA Analyzer
Autoplex Gen2

Print article

Channels

Molecular Diagnostics

view channel
Image: A new machine rapidly and robustly separates cancer cells from blood samples (Photo courtesy of DGIST)

Centrifugal System for Separating Circulating Tumor Cells from Blood Samples to Improve Cancer Diagnosis

Circulating tumor cells are cells that break off from cancers and are released into the blood stream. They can go on to form the seeds for new tumor formation in other parts of the body, known as metastases.... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.